Place · Level 3 · Condition

NAFLD / MASLD

全球 30% 成人 · 胰岛素抵抗驱动 · 减重 7-10% 是核心 · 2023 改名 MASLD · 与心血管/糖尿病共病

Story path

1MASLD · epidemiology + renamingMASLD · epidemiology + renaming
2Mechanism · IR + 2-hitMechanism · IR + 2-hit
3MASH · fibrosis + drug landscapeMASH · fibrosis + drug landscape
4Treatment · 7-10% weight lossTreatment · 7-10% weight loss
5I have fatty liver — what now?I have fatty liver — what now?

Chapter 1

MASLD · epidemiology + renaming

Non-alcoholic fatty liver disease (NAFLD) was renamed in 2023 by international consensus to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) (Rinella 2023). The rename happened because 'non-alcoholic' defined the disease by what it isn't; the true driver is metabolic dysfunction.

MASLD diagnostic criteria:

Imaging / histology shows hepatic steatosis ≥ 5%+ at least 1 cardiometabolic risk factor: overweight/obesity (BMI ≥ 25, Asia ≥ 23) / fasting glucose ≥ 5.6 / HbA1c ≥ 5.7% / BP ≥ 130/85 / TG ≥ 1.7 / HDL men < 1.0 women < 1.3
Epidemiology (Younossi 2018):

30% of adults globally29.2% in China, rising with BMI55-75% of type-2 diabetes patients75% of obese (BMI ≥ 30)
Clinical spectrum:

MAFL (simple steatosis): lipid deposition, no inflammationMASH (metabolic-associated steatohepatitis): steatosis + inflammation + hepatocyte ballooning, progressiveMASH fibrosis: F0-F4 staging, F3+ high cirrhosis/HCC riskCirrhosis: decompensation, transplant indication
Key knowledge updates:

MASLD is not benign: MASH 10-year cirrhosis progression 10-25%MASLD also increases cardiovascular mortality (CV disease is actually the #1 cause of death in MASLD, not liver disease)No specific drug (2024 resmetirom became first FDA-approved MASH drug, but only for F2-F3 + lifestyle)

Diagnosis + staging · is there fibrosis?

The most common misunderstanding about fatty liver: an ultrasound saying 'fatty liver' does not tell you how far the disease has gone. What determines prognosis is not the fat itself but whether fibrosis is present — so the focus of diagnosis is really on staging.

Step one is usually detecting fat. Routine abdominal ultrasound catches moderate-to-severe steatosis but is insensitive to mild (< 20%) fat; ALT can be entirely normal, so 'normal liver function' does not rule out MASLD. More sensitive tools are FibroScan's CAP value or MRI-PDFF, which quantify the fat fraction.

Step two is the decisive one — assessing fibrosis. The most practical are non-invasive scores:

FIB-4 index: computed from age, ALT, AST, and platelets — free, available any time. FIB-4 < 1.3 largely excludes advanced fibrosis; > 2.67 warrants further evaluation.NFS (NAFLD Fibrosis Score): similar idea, adds BMI and glucose.FibroScan elastography (LSM): transient elastography measures liver stiffness, more direct than a score.
Liver biopsy remains the gold standard but is invasive with sampling error; it is now reserved for cases where non-invasive assessment is ambiguous or for clinical-trial entry.

A reasonable sequence in practice: screen first with a free score like FIB-4 — low scorers just need periodic follow-up; intermediate-to-high scorers or those with high-risk substrate such as diabetes go on to FibroScan or hepatology referral. This puts limited testing resources on the people who actually need them.

Open this on the map

Chapter 2

Mechanism · IR + 2-hit

Driver: insulin resistance (IR) is the MASLD core.

First hit (steatosis):

IR → ↑ adipose lipolysis → free fatty acids (FFA) flood the liverHigh-carb/high-fructose diet → hepatic de novo lipogenesis (DNL) ↑ 3-5× (atlas fructose-uric-acid L4)VLDL export cannot keep up with influx → triglyceride accumulation
Second hit (inflammation → MASH):

Mitochondrial dysfunction → ↑ ROS (oxidative stress)Lipotoxicity: saturated fats / ceramides / DAGs activate inflammatory pathwaysGut-derived LPS (leaky gut) → Kupffer cell activation → / Hepatocyte death → stellate cell activation → fibrosis
Why some progress fast and others don't:

Genetics: PNPLA3 I148M variant is the most important genetic risk factor in AsiansMetabolic baseline: diabetes / high TG / hypertension → faster progressionLifestyle: high alcohol / sedentary / UPF / high fructose → acceleratesLean MASLD also exists (BMI < 25): mainly visceral fat + sarcopenia, can progress similarly (Kim 2017)
Connection to cardiovascular disease:

MASLD patients have 2× cardiovascular disease incidenceMASLD = early cardiovascular warning: same metabolic substrate, liver shows first, heart followsClinical implication: MASLD diagnosis = must assess and co-manage cardiovascular risk

Fructose + DNL · why sugary drinks hit the liver hardest

The 'de novo lipogenesis (DNL)' pathway inside the first hit deserves its own page, because it is the core mechanism by which sugary drinks and juice damage the liver — and why cutting sugar yields the largest single benefit in fatty liver.

Glucose can be used by cells all over the body; once insulin signals, muscle and adipose tissue share the load. Fructose is different: it is metabolized almost entirely in the liver, and its initial metabolism is not insulin-regulated and has no real energy gate (no key rate-limiting step like glucose has). That means the fructose in one large sugary drink lands concentrated on a single organ — the liver (Tappy 2010 review).

The liver cannot oxidize all that fructose in time, so it routes it through DNL into fatty acids and then triglycerides. In Stanhope 2009's controlled study, people drinking fructose beverages showed clear rises in visceral fat and hepatic DNL plus worse lipids, while an iso-caloric glucose-beverage group did not — same calories, completely different metabolic fate. Lustig 2013 summarizes it: not all sugar is equal; fructose's burden on the liver is uniquely concentrated.

That is why cutting sugary drinks and juice ranks first among MASLD dietary interventions. Note this refers to added sugar and concentrated juice — high-dose, fast-to-liver forms; the fructose in whole fruit is low-dose, wrapped in fiber, and absorbed far more slowly, so it is not in the same league and need not be feared.

Lean MASLD + genetics · you can have it without being overweight

Many assume fatty liver is a problem only for heavier people, but 'lean MASLD' is real — disease can occur at BMI < 25 (Kim 2017). Understanding this explains two things: why some lean people are found to have fatty liver, and why the same fatty liver leaves some people fine for decades while others progress quickly to cirrhosis.

The substrate of lean MASLD is usually a body-fat distribution problem, not total weight. People with poor subcutaneous fat-storage capacity more readily pile excess fat into viscera and liver (ectopic fat); meanwhile low muscle mass (sarcopenia) reduces where glucose can go, worsening insulin resistance. So someone who looks lean but has a large waist, little muscle, a sugary-drink habit, and a sedentary life can still be affected.

Genetics is an underrated factor too. The PNPLA3 I148M variant is the single most important genetic risk factor in Asian populations; carriers accumulate liver fat more readily on the same diet and progress more easily. This is not destiny — genes set the starting line, but diet, exercise, sugary drinks, and alcohol still drive the finish. Carriers of a high-risk genotype are, if anything, the people for whom solid lifestyle habits matter most.

Practical implication: when a check-up finds fatty liver, do not dismiss it because 'I'm not fat' — the fibrosis assessment, cardiovascular risk, and glucose/lipid work-up all still apply.

Open this on the map

Chapter 3

MASH · fibrosis + drug landscape

The truly dangerous inflection in fatty liver is the progression from simple steatosis (MAFL) to MASH (fat + inflammation + hepatocyte ballooning), and onward to fibrosis. Seeing this path clearly explains why clinicians watch the stage, not merely 'is there fat'.

Why fibrosis is the key:

Simple steatosis is long-term benign in most people; what determines liver outcomes is the degree of fibrosisF0-F2 carries lower risk; F3 (bridging fibrosis) + F4 (cirrhosis) drive cirrhosis, liver cancer, liver failure, and liver-related deathFibrosis stage is the single strongest predictor of long-term outcome — stronger than ALT, stronger than fat amount
How fibrosis forms:

Repeated lipotoxic + inflammatory injury to hepatocytes → activation of hepatic stellate cells (HSC)Activated stellate cells become myofibroblasts → secrete collagen → scarEarly fibrosis is reversible once the driver is removed (weight loss, metabolic control); after the structural changes of cirrhosis it is largely irreversible
Drug landscape — why a specific drug took so long:

For decades MASLD had no approved specific drug, because its driver is whole-body metabolism and a single target rarely moves it2024 resmetirom (Rezdiffra): first FDA-approved MASH-specific drug, a thyroid-hormone-receptor-β (THR-β) agonist that boosts hepatic fat oxidation. Limited to F2-F3, and must be added to lifestyle, not a replacementglucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. agonists (semaglutide / tirzepatide): primarily glucose-lowering / weight-loss drugs, but potent weight loss drives MASH histologic improvement in trials. Especially fitting for patients with comorbid obesity / T2DVitamin E 800 IU/day: an option for non-diabetic MASH (PIVENS RCT); long-term high dose has cardiovascular concerns, not for everyonePioglitazone: improves MASH histology but with weight gain + heart-failure risk; selective use
This island's stance: even in the era of an available drug, weight loss and metabolic management remain the foundation; drugs are an add-on, not a shortcut around lifestyle.

Open this on the map

Chapter 4

Treatment · 7-10% weight loss

Core treatment is weight + metabolism, not drugs (Vilar-Gomez 2015 landmark RCT).

Weight-loss dose-response benefits:

3-5% loss: liver fat ↓ 30-50%7% loss: MASH improvement (inflammation + ballooning) 60-80%10%+ loss: even fibrosis can reverse in ~ 45% of patients
Diet (strong evidence):

Mediterranean diet: current guideline first-line (high MUFA / polyphenols / fish / produce / whole grains)Limit sugar + fructose: sugary drinks / juice are the top hepatic burden — quitting yields the largest single benefitLimit ultra-processed foods (UPF): triple hit of high fat + high sugar + additivesNo need for extreme low-fat or low-carb: emphasize quality, not extreme ratios
Exercise (effective independent of weight loss):

Aerobic 150-200 min/week → liver fat ↓ even without weight lossResistance training: improves insulin sensitivity, preserves muscleCombined > single mode: aerobic + resistance beats aerobic alone
Alcohol:

MASLD patients should limit alcohol to < 30 g/day men, 20 g/day women (low-risk threshold)MASH + fibrosis F2+: complete abstinence (alcohol + MASH synergistically accelerate fibrosis)
Drugs (adjunct):

Vitamin E 800 IU/day: non-diabetic MASH patients (PIVENS RCT), long-term high-dose has cardiovascular concernsPioglitazone: improves MASH histology, but weight gain + heart-failure riskglucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. receptor agonists (semaglutide / tirzepatide): potent weight loss → MASH improvement, 2024 STEP-HFpEF / ESSENCE showed MASH improvementResmetirom (Rezdiffra) 2024 FDA: first MASH-specific drug (THR-β agonist), limited to F2-F3, must add to lifestyle
Monitoring:

At diagnosis: assess fibrosis (FIB-4 / NFS score, FibroScan elastography)Every 1-3 years: repeat liver function + FIB-4 + metabolic + cardiovascular assessmentF3+: hepatology referral + HCC screening (US every 6 months)
Atlas connections:

type-2-diabetes (70% comorbidity)fructose-metabolism + ultra-processed-foods + alcohol-metabolism (dietary triggers)hypertension + dyslipidemia (metabolic-syndrome same source)fasting-time-restricted (clinical evidence developing, not strongly endorsed)L4 mtor-pathway + fructose-uric-acid (mechanism)

Open this on the map

Chapter 5

I have fatty liver — what now?

'My check-up reported fatty liver — what now?' You can think it through with a few questions, rather than panicking or shrugging it off from the start.

Q1 · What stage is it (staging first)?

Compute a FIB-4 first (age + ALT + AST + platelets, free)FIB-4 < 1.3: advanced fibrosis unlikely — focus on lifestyle + periodic follow-upFIB-4 ≥ 1.3 or high-risk substrate such as diabetes: go on to FibroScan or hepatology referralDon't conclude from the ultrasound word 'fatty liver' alone, and don't assume all is well just because ALT is normal
Q2 · What is my metabolic substrate?

Fatty liver almost never appears alone — it is metabolic syndrome's projection onto the liverCheck in parallel: fasting glucose / HbA1c (diabetes) + lipids (dyslipidemia) + blood pressure (hypertension) + waistCardiovascular disease is the #1 cause of death in fatty-liver patients, so the cardiovascular risk assessment cannot be skipped
Q3 · What is my strongest lever?

7-10% weight loss is the single strongest intervention (3-5% lowers liver fat, 7% improves inflammation, 10%+ reverses fibrosis in some)Cut sugary drinks + juice: directly removes the main raw material for hepatic DNL — fastest payoffAerobic + resistance training: liver fat drops even when weight barely movesLimit alcohol: fatty liver + alcohol synergistically damage the liver — full abstinence advised at F2+
Q4 · Do I need a drug?

Most early patients: do the lifestyle work solidly for 3-6 months, then reassessComorbid obesity / T2D: agonists treat metabolism and improve the liver — discuss with a doctorF2-F3 MASH: resmetirom is a new option, but still added to lifestyleNo drug is a shortcut around weight loss
Q5 · How often to recheck?

Low risk: every 1-3 years recheck liver function + FIB-4 + metabolic + cardiovascularF3+: hepatology referral + liver-cancer screening (abdominal ultrasound every 6 months)
Red flags — seek care immediately: yellowing of skin or eyes (jaundice) / markedly distended abdomen (ascites) / vomiting blood or black stools (GI bleeding) / confusion or drowsiness (hepatic encephalopathy). These signal decompensated cirrhosis — not a 'let's keep watching' situation.

This island's core stance: in its early-to-mid stages fatty liver is an interveneable, often reversible metabolic state, not a sentence. It is more like an early metabolic warning slip your body hands you — read it, follow the weight-loss and metabolic main line, and most people can press down the long-term risk to liver and heart together.

Open this on the map